28424683|t|Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients
28424683|a|Natural killer (NK) cells are known to target cancer stem cells and undifferentiated tumors. In this paper, we provide a novel strategy for expanding large numbers of super-charged NK cells with significant potential to lyse and differentiate cancer stem cells and demonstrate the differences in the dynamics of NK cell expansion between healthy donors and cancer patients. Decline in cytotoxicity and lower interferon (IFN)-γ secretion by osteoclast (OC)-expanded NK cells from cancer patients correlates with faster expansion of residual contaminating T cells within purified NK cells, whereas healthy donors ' OCs continue expanding super-charged NK cells while limiting T cell expansion for up to 60 days. Similar to patient NK cells, NK cells from tumor -bearing BLT-humanized mice promote faster expansion of residual T cells resulting in decreased numbers and function of NK cells, whereas NK cells from mice with no tumor continue expanding NK cells and retain their cytotoxicity. In addition, dendritic cells (DCs) in contrast to OCs are found to promote faster expansion of residual T cells within purified NK cells resulting in the decline in NK cell numbers from healthy individuals. Addition of anti-CD3 mAb inhibits T cell proliferation while enhancing NK cell expansion; however, expanding NK cells have lower cytotoxicity but higher secretion of IFN-γ. Expansion and functional activation of super-charged NK cells by OCs is dependent on interleukin (IL)-12 and IL-15. Thus, in this report, we not only provide a novel strategy to expand super-charged NK cells, but also demonstrate that rapid and sustained expansion of residual T cells within the purified NK cells during expansion with DCs or OCs could be a potential mechanism by which the numbers and function of NK cells decline in cancer patients and in BLT-humanized mice.
28424683	0	14	Novel Strategy	T062	UMLS:C0035171
28424683	25	47	Super-Charged NK Cells	T017	UMLS:C0022688
28424683	78	82	Lyse	T038	UMLS:C0024348
28424683	101	118	Cancer Stem Cells	T017	UMLS:C1956422
28424683	135	147	NK Expansion	T038	UMLS:C0007595
28424683	169	176	Healthy	T098	UMLS:C1708335
28424683	197	222	Natural killer (NK) cells	T017	UMLS:C0022688
28424683	243	260	cancer stem cells	T017	UMLS:C1956422
28424683	265	288	undifferentiated tumors	T038	UMLS:C0205698
28424683	318	332	novel strategy	T062	UMLS:C0035171
28424683	364	386	super-charged NK cells	T017	UMLS:C0022688
28424683	417	421	lyse	T038	UMLS:C0024348
28424683	440	457	cancer stem cells	T017	UMLS:C1956422
28424683	509	516	NK cell	T017	UMLS:C0022688
28424683	517	526	expansion	T038	UMLS:C0007595
28424683	535	549	healthy donors	T098	UMLS:C0013018
28424683	571	594	Decline in cytotoxicity	T033	UMLS:C1849420
28424683	599	604	lower	T082	UMLS:C0441994
28424683	605	633	interferon (IFN)-γ secretion	T038	UMLS:C3156720
28424683	637	647	osteoclast	T017	UMLS:C0029431
28424683	649	651	OC	T017	UMLS:C0029431
28424683	662	670	NK cells	T017	UMLS:C0022688
28424683	715	724	expansion	T038	UMLS:C0007595
28424683	751	758	T cells	T017	UMLS:C0039194
28424683	775	783	NK cells	T017	UMLS:C0022688
28424683	793	807	healthy donors	T098	UMLS:C0013018
28424683	810	813	OCs	T017	UMLS:C0029431
28424683	833	855	super-charged NK cells	T017	UMLS:C0022688
28424683	871	877	T cell	T017	UMLS:C0039194
28424683	878	887	expansion	T038	UMLS:C0007595
28424683	926	934	NK cells	T017	UMLS:C0022688
28424683	936	944	NK cells	T017	UMLS:C0022688
28424683	950	955	tumor	T038	UMLS:C0027651
28424683	965	983	BLT-humanized mice	T038	UMLS:C2986594
28424683	999	1008	expansion	T038	UMLS:C0007595
28424683	1021	1059	T cells resulting in decreased numbers	T033	UMLS:C2673541
28424683	1076	1084	NK cells	T017	UMLS:C0022688
28424683	1094	1102	NK cells	T017	UMLS:C0022688
28424683	1108	1112	mice	T204	UMLS:C0025929
28424683	1118	1120	no	T033	UMLS:C1513916
28424683	1121	1126	tumor	T038	UMLS:C0027651
28424683	1136	1145	expanding	T038	UMLS:C0007595
28424683	1146	1154	NK cells	T017	UMLS:C0022688
28424683	1172	1184	cytotoxicity	T038	UMLS:C0596402
28424683	1199	1214	dendritic cells	T017	UMLS:C0011306
28424683	1216	1219	DCs	T017	UMLS:C0011306
28424683	1236	1239	OCs	T017	UMLS:C0029431
28424683	1268	1277	expansion	T038	UMLS:C0007595
28424683	1290	1297	T cells	T017	UMLS:C0039194
28424683	1314	1322	NK cells	T017	UMLS:C0022688
28424683	1340	1366	decline in NK cell numbers	T033	UMLS:C2363838
28424683	1372	1391	healthy individuals	T098	UMLS:C1708335
28424683	1405	1417	anti-CD3 mAb	T103	UMLS:C3831520
28424683	1427	1447	T cell proliferation	T038	UMLS:C1155046
28424683	1464	1471	NK cell	T017	UMLS:C0022688
28424683	1472	1481	expansion	T038	UMLS:C0007595
28424683	1492	1501	expanding	T038	UMLS:C0007595
28424683	1502	1510	NK cells	T017	UMLS:C0022688
28424683	1516	1521	lower	T082	UMLS:C0441994
28424683	1522	1534	cytotoxicity	T038	UMLS:C0596402
28424683	1546	1564	secretion of IFN-γ	T038	UMLS:C3156720
28424683	1566	1575	Expansion	T038	UMLS:C0007595
28424683	1605	1627	super-charged NK cells	T017	UMLS:C0022688
28424683	1631	1634	OCs	T017	UMLS:C0029431
28424683	1651	1670	interleukin (IL)-12	T103	UMLS:C0123759
28424683	1675	1680	IL-15	T103	UMLS:C0254610
28424683	1726	1740	novel strategy	T062	UMLS:C0035171
28424683	1744	1750	expand	T038	UMLS:C0007595
28424683	1751	1773	super-charged NK cells	T017	UMLS:C0022688
28424683	1801	1830	rapid and sustained expansion	T038	UMLS:C0007595
28424683	1843	1850	T cells	T017	UMLS:C0039194
28424683	1871	1879	NK cells	T017	UMLS:C0022688
28424683	1887	1896	expansion	T038	UMLS:C0007595
28424683	1902	1905	DCs	T017	UMLS:C0011306
28424683	1909	1912	OCs	T017	UMLS:C0029431
28424683	1981	1997	NK cells decline	T033	UMLS:C2363838
28424683	2024	2042	BLT-humanized mice	T038	UMLS:C2986594